{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:31:28Z","timestamp":1793194288224,"version":"4.5.0"},"reference-count":112,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.autrev.2021.103019","type":"journal-article","created":{"date-parts":[[2021,12,15]],"date-time":"2021-12-15T20:35:54Z","timestamp":1639600554000},"page":"103019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Efficacy of intravenous immunoglobulin in autoimmune neurological diseases. Literature systematic review and meta-analysis"],"prefix":"10.1016","volume":"21","author":[{"given":"Valeria","family":"Morales-Ruiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor Hugo","family":"Ju\u00e1rez-Vaquera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos","family":"Rosetti-Sciutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fausto","family":"S\u00e1nchez-Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Adalid-Peralta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2021.103019_bb0005","series-title":"Inmunolog\u00eda Celular y Molecular","author":"Abbas","year":"2008"},{"key":"10.1016\/j.autrev.2021.103019_bb0010","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJM200108023450506","article-title":"Advances in immunology","volume":"345","author":"Davidson","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.103019_bb0015","series-title":"Autoinmunidad y Enfermedad Autoinmune, Colombia: CIB Fondo Editorial","first-page":"53","article-title":"Receptores Fc\u03b3 y autoinmunidad","author":"G\u00f3mez","year":"2005"},{"key":"10.1016\/j.autrev.2021.103019_bb0020","first-page":"1","article-title":"Histoire des maladies neurologiques auto-immunes","author":"Humbel","year":"2014","journal-title":"Groupe d\u2019Etude de l\u2019Auto-Immunit\u00e9 L\u2019Info"},{"key":"10.1016\/j.autrev.2021.103019_bb0025","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2004.04.002","article-title":"The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence-based indications and safety profile","volume":"102","author":"Dalakas","year":"2004","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.autrev.2021.103019_bb0030","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1038\/nrneurol.2014.253","article-title":"Intravenous immunoglobulin in neurology-mode of action and clinical efficacy","volume":"11","author":"L\u00fcnemann","year":"2015","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0035","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00063030-200216010-00005","article-title":"Mechanisms of intravenous immunoglobulin action in the treatment of autoimmune disorders","volume":"16","author":"Larroche","year":"2002","journal-title":"BioDrugs"},{"key":"10.1016\/j.autrev.2021.103019_bb0040","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jneuroim.2010.09.015","article-title":"Plasma exchange and intravenous immunoglobulins: mechanism of action in immune-mediated neuropathies","volume":"231","author":"Lehmann","year":"2011","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2021.103019_bb0045","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1136\/practneurol-2019-002336","article-title":"Plasma exchange in neurological disease","volume":"20","author":"Osman","year":"2020","journal-title":"Pract Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0050","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/bjh.15903","article-title":"The role of plasma exchange in the management of autoimmune disorders","volume":"186","author":"Zanatta","year":"2019","journal-title":"Br J Haematol"},{"key":"10.1016\/j.autrev.2021.103019_bb0055","first-page":"163","article-title":"Plasmaf\u00e9resis y recambio plasm\u00e1tico","volume":"61","author":"Barba","year":"2014","journal-title":"Rev Latin Patol Cl\u00edn Med Lab"},{"key":"10.1016\/j.autrev.2021.103019_bb0060","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1056\/NEJMra1009433","article-title":"Intravenous immune globulin in autoimmune and inflammatory diseases","volume":"367","author":"Gelfand","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.103019_bb0065","article-title":"Les anticorps anti-gangliosides: int\u00e9r\u00eats et limites dans les neuropathies p\u00e9riph\u00e9riques autoimmunes","volume":"2016","author":"H\u00fce","year":"2016","journal-title":"Revue Francophone Des Lab"},{"key":"10.1016\/j.autrev.2021.103019_bb0070","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1212\/CON.0000000000000513","article-title":"Guillain-Barr\u00e9 Syndrome","volume":"23","author":"Donofrio","year":"2017","journal-title":"Continuum (Minneapolis, Minn)"},{"key":"10.1016\/j.autrev.2021.103019_bb0075","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.autrev.2016.09.022","article-title":"Guillain-Barr\u00e9 syndrome","volume":"16","author":"Esposito","year":"2017","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2021.103019_bb0080","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/S1734-1140(10)70261-9","article-title":"Guillain-Barr\u00e9 syndrome (GBS)","volume":"62","author":"Pithadia","year":"2010","journal-title":"Pharmacol Rep"},{"key":"10.1016\/j.autrev.2021.103019_bb0085","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"van den Berg","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0090","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3109\/00207454.2014.913588","article-title":"Pathophysiology and diagnosis of Guillain-Barr\u00e9 syndrome-challenges and needs","volume":"125","author":"Dash","year":"2015","journal-title":"Int J Neurosci"},{"key":"10.1016\/j.autrev.2021.103019_bb0095","first-page":"540","article-title":"Enfermedades neurol\u00f3gicas de vigilancia y notificaci\u00f3n obligatoria: Tendencia y desenlace en un instituto neurol\u00f3gico del Sistema Nacional de Salud de la Ciudad de M\u00e9xico, de 2005 a 2011","volume":"150","author":"Vel\u00e1squez-P\u00e9rez","year":"2014","journal-title":"Gac Med Mex"},{"key":"10.1016\/j.autrev.2021.103019_bb0100","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(16)00339-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"388","author":"Willison","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2021.103019_bb0105","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.it.2013.05.001","article-title":"Glycolipid antigens and autoantibodies in autoimmune neuropathies","volume":"34","author":"Willison","year":"2013","journal-title":"Trends Immunol"},{"key":"10.1016\/j.autrev.2021.103019_bb0110","first-page":"95","article-title":"S\u00edndrome de Guillain Barr\u00e9: patogenia, diagn\u00f3stico y cuidados cr\u00edticos en pediatr\u00eda","volume":"73","author":"S\u00e1nchez Miranda","year":"2001","journal-title":"Rev Cubana Pediatr"},{"key":"10.1016\/j.autrev.2021.103019_bb0115","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1055\/s-0039-1693005","article-title":"Guillain-Barre syndrome","volume":"39","author":"Malek","year":"2019","journal-title":"Semin Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0120","series-title":"Guillain Barre Syndrome (Nursing)","author":"Nguyen","year":"2021"},{"key":"10.1016\/j.autrev.2021.103019_bb0125","first-page":"2568","article-title":"Immunotherapy of Guillain-Barre syndrome","volume":"14","author":"Liu","year":"2018","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.autrev.2021.103019_bb0130","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jaut.2014.01.003","article-title":"Diagnostic and clinical classification of autoimmune myasthenia gravis","volume":"48\u201349","author":"Berrih-Aknin","year":"2014","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2021.103019_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir","year":"2018","journal-title":"Neurol Clin"},{"key":"10.1016\/j.autrev.2021.103019_bb0140","first-page":"7","article-title":"Recent advances in understanding and managing myasthenia gravis","author":"Jordan","year":"2018","journal-title":"F1000Research"},{"key":"10.1016\/j.autrev.2021.103019_bb0145","first-page":"47","article-title":"Miastenia gravis (MG) en adultos de instituciones pertenecientes al sistema p\u00fablico sanitario mexicano: un an\u00e1lisis de egresos hospitalarios durante el a\u00f1o 2010","volume":"151","author":"Tolosa-Tort","year":"2015","journal-title":"Gac Med Mex"},{"key":"10.1016\/j.autrev.2021.103019_bb0150","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/S1474-4422(09)70063-8","article-title":"Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity","volume":"8","author":"Meriggioli","year":"2009","journal-title":"Lancet Neuro"},{"key":"10.1016\/j.autrev.2021.103019_bb0155","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1055\/s-0035-1558975","article-title":"Myasthenia gravis","volume":"35","author":"Gwathmey","year":"2015","journal-title":"Semin Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0160","series-title":"Disfagia Asociada a Miastenia Gravis Como Factor de Riesgo en el Estado Nutricio","author":"Garc\u00eda-L\u00f3pez","year":"2014"},{"key":"10.1016\/j.autrev.2021.103019_bb0165","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrneurol.2016.44","article-title":"Myasthenia gravis - autoantibody characteristics and their implications for therapy","volume":"12","author":"Gilhus","year":"2016","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0170","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1080\/14737175.2018.1491310","article-title":"Advances in autoimmune myasthenia gravis management","volume":"18","author":"Wang","year":"2018","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.autrev.2021.103019_bb0175","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/cei.12217","article-title":"Myasthenia gravis: an update for the clinician","volume":"175","author":"Sieb","year":"2014","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2021.103019_bb0180","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1007\/s00415-016-8045-z","article-title":"Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the guidelines of the German neurological society","volume":"263","author":"Melzer","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0185","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/WCO.0000000000000858","article-title":"Progress in the therapy of myasthenia gravis: getting closer to effective targeted immunotherapies","volume":"33","author":"Dalakas","year":"2020","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0190","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1038\/s41582-018-0110-z","article-title":"Immunotherapy in myasthenia gravis in the era of biologics","volume":"15","author":"Dalakas","year":"2019","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0195","first-page":"1","volume":"18","author":"Vargas-Ca\u00f1as","year":"2017","journal-title":"Revista Mexicana de Neurociencia Noviembre-Diciembre"},{"key":"10.1016\/j.autrev.2021.103019_bb0200","doi-asserted-by":"crossref","first-page":"656","DOI":"10.33588\/rn.4611.2007179","article-title":"Polirradiculoneuropat\u00eda cr\u00f3nica inflamatoria desmielinizante. Experiencia de 10 a\u00f1os en un Centro Mexicano","volume":"46","author":"San-Juan","year":"2008","journal-title":"Rev Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0205","first-page":"1","article-title":"Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment","author":"Lehmann","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2021.103019_bb0210","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jaut.2019.04.021","article-title":"Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease","volume":"102","author":"Rodr\u00edguez","year":"2019","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2021.103019_bb0215","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.nmd.2016.10.008","article-title":"Paranodal lesions in chronic inflammatory demyelinating polyneuropathy associated with anti-Neurofascin 155 antibodies","volume":"27","author":"Vallat","year":"2017","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.autrev.2021.103019_bb0220","first-page":"221","article-title":"Polirradiculoneuropat\u00eda cr\u00f3nica inflamatoria desmielinizante Art\u00edculo original","volume":"12","author":"Castro-Mac\u00edas","year":"2007","journal-title":"Et al Arch Neurocien (Mex)"},{"key":"10.1016\/j.autrev.2021.103019_bb0225","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1055\/s-0039-1693008","article-title":"Chronic inflammatory demyelinating Polyradiculoneuropathy","volume":"39","author":"Shije","year":"2019","journal-title":"Semin Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0230","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/S1474-4422(19)30144-9","article-title":"Progress in diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy","volume":"18","author":"Bunschoten","year":"2019","journal-title":"Lancet Neuro"},{"key":"10.1016\/j.autrev.2021.103019_bb0235","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1002\/ana.410110205","article-title":"Prednisone improves chronic inflammatory demyelinating polyrdcdoneuropathy more than no treatment","volume":"11","author":"Dyck","year":"1982","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0240","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/S1474-4422(10)70021-1","article-title":"Pulsed high-dose dexamethasone versus standard prednisolone treatment for chronic infl ammatory demyelinating polyradiculoneuropathy (PREDICT study): a double-blind, randomised, controlled trial","volume":"9","author":"van Schaik","year":"2010","journal-title":"Lancet Neuro"},{"key":"10.1016\/j.autrev.2021.103019_bb0245","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1002\/ana.1088","article-title":"Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"50","author":"Hughes","year":"2001","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0250","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/S1474-4422(07)70329-0","article-title":"Intravenous immune globulin (10% caprylate-chromatography purifi ed) for the treatment of chronic infl ammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial","volume":"7","author":"Hughes","year":"2008","journal-title":"Lancet Neuro"},{"key":"10.1016\/j.autrev.2021.103019_bb0255","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1002\/ana.410360607","article-title":"A plasma exchange versus immune Globultn I h s i o n trial in chronic I d m a t o r y demyelinating polyradiculoneuropath","volume":"36","author":"Dyck","year":"1994","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0260","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1056\/NEJMra1708712","article-title":"Antibody-mediated encephalitis","volume":"378","author":"Dalmau","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.103019_bb0265","first-page":"54","article-title":"Encefalitis autoinmunes. Receptor anti-NMDA Y nuevos inmunofenotipos","volume":"79","author":"Erazo","year":"2019","journal-title":"Medicina"},{"key":"10.1016\/j.autrev.2021.103019_bb0270","doi-asserted-by":"crossref","first-page":"274","DOI":"10.18233\/APM38No4pp274-2791436","article-title":"Autoimmune encephalitis in pediatrics","volume":"38","author":"Garc\u00eda-Berist\u00e1in","year":"2017","journal-title":"Acta Pediatr Mexico"},{"key":"10.1016\/j.autrev.2021.103019_bb0275","article-title":"Autoimmune encephalitis","volume":"66","author":"Guasp","year":"2018","journal-title":"Rev Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0280","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.braindev.2013.10.005","article-title":"Anti-NMDAR autoimmune encephalitis","volume":"36","author":"Miya","year":"2014","journal-title":"Brain Dev"},{"key":"10.1016\/j.autrev.2021.103019_bb0285","first-page":"389","article-title":"Update on the diagnosis and management of autoimmune encephalitis","volume":"20","author":"Ellul","year":"2020","journal-title":"Clin Med J Royal College Phys Lond"},{"key":"10.1016\/j.autrev.2021.103019_bb0290","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1007\/s10072-019-03930-3","article-title":"Management of antibody-mediated autoimmune encephalitis in adults and children: literature review and consensus-based practical recommendations","volume":"40","author":"Zuliani","year":"2019","journal-title":"Neurol Sci"},{"key":"10.1016\/j.autrev.2021.103019_bb0295","article-title":"Encefalitis por anticuerpos contra el receptor de NMDA","author":"Guasp","year":"2017","journal-title":"Med Clin"},{"key":"10.1016\/j.autrev.2021.103019_bb0300","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/eye.2011.81","article-title":"Optic neuritis","volume":"25","author":"Pau","year":"2011","journal-title":"Eye (Lond)"},{"key":"10.1016\/j.autrev.2021.103019_bb0305","first-page":"95","article-title":"Revista M\u00e9dica Revista M\u00e9dica MD","volume":"9","author":"Hern\u00e1ndez-Castro","year":"2017","journal-title":"Rev Med"},{"key":"10.1016\/j.autrev.2021.103019_bb0310","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ophtha.2019.09.032","article-title":"Population-based incidence of pediatric and adult optic neuritis and the risk of multiple sclerosis","volume":"127","author":"Lee","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.autrev.2021.103019_bb0315","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.survophthal.2019.06.001","article-title":"Critical review: typical and atypical optic neuritis","volume":"64","author":"Abel","year":"2019","journal-title":"Surv Ophthalmol"},{"key":"10.1016\/j.autrev.2021.103019_bb0320","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1212\/CON.0000000000000768","article-title":"Optic neuritis","volume":"25","author":"Bennett","year":"2019","journal-title":"Continuum (Minneapolis, Minn)"},{"key":"10.1016\/j.autrev.2021.103019_bb0325","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(13)70259-X","article-title":"Optic neuritis","volume":"13","author":"Toosy","year":"2014","journal-title":"Lancet Neuro"},{"key":"10.1016\/j.autrev.2021.103019_bb0330","doi-asserted-by":"crossref","first-page":"249","DOI":"10.4321\/S1137-66272009000300011","article-title":"Neuritis \u00f3ptica inflamatoria","volume":"32","author":"Ayuso","year":"2009","journal-title":"An Sist Sanit Navar"},{"key":"10.1016\/j.autrev.2021.103019_bb0335","first-page":"82","article-title":"Optic neuritis: a review","volume":"16","author":"Shams","year":"2009","journal-title":"Int MS J"},{"key":"10.1016\/j.autrev.2021.103019_bb0340","doi-asserted-by":"crossref","DOI":"10.1097\/WNO.0000000000000700","article-title":"Acute management of optic neuritis: an evolving paradigm","volume":"38","author":"Horton","year":"2018","journal-title":"J Neuroophthalmol"},{"key":"10.1016\/j.autrev.2021.103019_bb0345","doi-asserted-by":"crossref","DOI":"10.1007\/s11910-019-1014-z","article-title":"Clinical characteristics and treatment of MOG-IgG-associated optic neuritis","volume":"19","author":"Tajfirouz","year":"2019","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1016\/j.autrev.2021.103019_bb0350","article-title":"Progressive multiple sclerosis: from pathogenic mechanisms to treatment","volume":"140","author":"Correale","year":"2017","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2021.103019_bb0355","doi-asserted-by":"crossref","DOI":"10.1097\/WCO.0000000000000622","article-title":"Multiple sclerosis: clinical aspects","volume":"31","author":"Oh","year":"2018","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0360","doi-asserted-by":"crossref","DOI":"10.1016\/j.coi.2017.08.013","article-title":"Immunomodulation in multiple sclerosis: promises and pitfalls","volume":"49","author":"Dendrou","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2021.103019_bb0365","article-title":"Multiple sclerosis","volume":"87","author":"Nicholas","year":"2013","journal-title":"Am Fam Physician"},{"key":"10.1016\/j.autrev.2021.103019_bb0370","doi-asserted-by":"crossref","DOI":"10.1111\/j.0105-2896.2005.00240.x","article-title":"Multiple sclerosis","volume":"204","author":"Hafler","year":"2005","journal-title":"Immunol Rev"},{"key":"10.1016\/j.autrev.2021.103019_bb0375","article-title":"Update on immunopathogenesis and immunotherapy in multiple sclerosis","volume":"2","author":"Selter","year":"2013","journal-title":"ImmunTarget Ther"},{"key":"10.1016\/j.autrev.2021.103019_bb0380","doi-asserted-by":"crossref","DOI":"10.1056\/NEJM199801293380502","article-title":"Axonal transection in the lesions of multiple sclerosis","volume":"338","author":"Trapp","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.103019_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2020.05.049","article-title":"Treatment of multiple sclerosis: a review","volume":"133","author":"Hauser","year":"2020","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2021.103019_bb0390","first-page":"16","article-title":"Multiple sclerosis, a treatable disease","author":"Doshi","year":"2016","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.autrev.2021.103019_bb0395","article-title":"Current and emerging treatment of multiple sclerosis","volume":"22","author":"Hart","year":"2016","journal-title":"Am J Manag Care"},{"key":"10.1016\/j.autrev.2021.103019_bb0400","doi-asserted-by":"crossref","DOI":"10.1111\/ene.13819","article-title":"Multiple sclerosis - a review","volume":"26","author":"Dobson","year":"2019","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0405","series-title":"R: A Language and Environment for Statistical Computing","author":"R Core Team","year":"2021"},{"key":"10.1016\/j.autrev.2021.103019_bb0410","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.56.1.36","article-title":"Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study","volume":"56","author":"Vermeulen","year":"1993","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2021.103019_bb0415","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/brain\/119.4.1067","article-title":"Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study","volume":"119","author":"Hahn","year":"1996","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2021.103019_bb0420","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/BF00868527","article-title":"A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"243","author":"Thompson","year":"1996","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0425","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1212\/WNL.56.4.445","article-title":"Randomized controlled trial of mg in untreated chronic inflammatory demyelinating polyradiculoneuropathy","volume":"56","author":"Mendell","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2021.103019_bb0430","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S0140-6736(96)09377-4","article-title":"Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis","volume":"349","author":"Fazekas","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2021.103019_bb0435","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1212\/WNL.50.2.398","article-title":"Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses","volume":"50","author":"Achiron","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2021.103019_bb0440","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1177\/135245850000602S03","article-title":"The Austrian Immunoglobulin in MS (AIMS) study: final analysis","volume":"6","author":"Strasser-Fuchs","year":"2000","journal-title":"Multiple Sclerosis (Houndmills, Basingstoke, England)"},{"key":"10.1016\/j.autrev.2021.103019_bb0445","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00234-003-1088-8","article-title":"The role of qualitative and quantitative MRI assessment of multiple sclerosis lesions according to their in evaluating the efficacy of intravenous immunoglobulin G","volume":"46","author":"Ko\u00e7er","year":"2004","journal-title":"Neuroradiology"},{"key":"10.1016\/j.autrev.2021.103019_bb0450","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1212\/01.wnl.0000318281.98220.6f","article-title":"Intravenous immunoglobulin in relapsing-remitting multiple sclerosis: a dose-finding trial","volume":"71","author":"Fazekas","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2021.103019_bb0455","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1056\/NEJM199204233261705","article-title":"A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barr\u00e9 syndrome. Dutch Guillain-Barr\u00e9 Study Group","volume":"326","author":"van der Mech\u00e9","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2021.103019_bb0460","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1212\/WNL.46.1.100","article-title":"Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barr\u00e9 syndrome","volume":"46","author":"Bril","year":"1996","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2021.103019_bb0465","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/1097-4598(200101)24:1<54::AID-MUS6>3.0.CO;2-9","article-title":"Intravenous immunoglobulin therapy for Guillain-Barr\u00e9 syndrome with IgG anti-GM1 antibody","volume":"24","author":"Kuwabara","year":"2001","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2021.103019_bb0470","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/cc10305","article-title":"Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barr\u00e9 syndrome: a randomized study","volume":"15","author":"El-Bayoumi","year":"2011","journal-title":"Crit Care"},{"key":"10.1016\/j.autrev.2021.103019_bb0475","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/tme.12169","article-title":"Comparison on therapeutic effect of plasma exchange and intravenous immunoglobulin for Guillian-Barre syndrome","volume":"25","author":"Ye","year":"2015","journal-title":"Transfus Med (Oxford, England)"},{"key":"10.1016\/j.autrev.2021.103019_bb0480","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1002\/ana.410410615","article-title":"Clinical trial of plasma exchange and high-dose intravenous immunoglobulin in myasthenia gravis","volume":"41","author":"Gajdos","year":"1997","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0485","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/j.1744-9987.2009.00751.x","article-title":"Comparing the autoantibody levels and clinical efficacy of double filtration plasmapheresis, immunoadsorption, and intravenous immunoglobulin for the treatment of late-onset myasthenia gravis","volume":"14","author":"Liu","year":"2010","journal-title":"Ther Apher Dial"},{"key":"10.1016\/j.autrev.2021.103019_bb0490","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1212\/WNL.0b013e31821e5505","article-title":"Comparison of IVIg and PLEX in patients with myasthenia gravis","volume":"76","author":"Barth","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2021.103019_bb0495","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s40120-019-00156-5","article-title":"Treatment effectiveness for resolution of multiple sclerosis relapse in a US health plan population","volume":"8","author":"Nazareth","year":"2019","journal-title":"Neurol Ther"},{"key":"10.1016\/j.autrev.2021.103019_bb0500","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1017\/cjn.2016.13","article-title":"Limbic encephalitis associated with GAD65 antibodies: brief review of the relevant literature","volume":"43","author":"Gagnon","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"10.1016\/j.autrev.2021.103019_bb0505","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s12868-020-00561-9","article-title":"Intravenous methylprednisolone or immunoglobulin for anti-glutamic acid decarboxylase 65 antibody autoimmune encephalitis: which is better?","volume":"21","author":"Li","year":"2020","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.autrev.2021.103019_bb0510","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/s10384-020-00790-9","article-title":"Intravenous immunoglobulin treatment for steroid-resistant optic neuritis: a multicenter, double-blind, randomized, controlled phase III study","volume":"65","author":"Mimura","year":"2021","journal-title":"Jpn J Ophthalmol"},{"key":"10.1016\/j.autrev.2021.103019_bb0520","doi-asserted-by":"crossref","DOI":"10.1016\/S0165-5728(02)00430-7","article-title":"Intravenous immunoglobulin modulates lymphocyte CD54 and monocyte FcgammaRII expression in patients with chronic inflammatory neuropathies","volume":"135","author":"Cr\u00e9ange","year":"2003","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2021.103019_bb0525","article-title":"Treatment of multiple sclerosis with IVIg: potential effects and methodology of clinical trials","volume":"57 Suppl","author":"S\u00f8rensen","year":"1994","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2021.103019_bb0530","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jneuroim.2013.01.001","article-title":"Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy - a new mechanism of action?","volume":"256","author":"Bick","year":"2013","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2021.103019_bb0535","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jneuroim.2014.06.007","article-title":"IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"274","author":"Ritter","year":"2014","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2021.103019_bb0540","doi-asserted-by":"crossref","DOI":"10.1001\/archneur.1993.00540040069017","article-title":"Immunoglobulin G immunosuppression of multiple sclerosis. Suppression of all three major lymphocyte subsets","volume":"50","author":"Tenser","year":"1993","journal-title":"Arch Neurol"},{"key":"10.1016\/j.autrev.2021.103019_bb0545","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.4049\/jimmunol.1201965","article-title":"Intravenous gammaglobulin inhibits encephalitogenic potential of pathogenic T cells and interferes with their trafficking to the central nervous system, implicating sphingosine-1 phosphate receptor 1\u2013mammalian target of rapamycin axis","volume":"190","author":"Othy","year":"2013","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2021.103019_bb0550","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1517\/14656566.2011.564160","article-title":"The role of immunotherapy in Guillain-Barr\u00e9 syndrome: understanding the mechanism of action","volume":"12","author":"Shahrizaila","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.autrev.2021.103019_bb0555","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001798.pub2","article-title":"Plasma exchange for Guillain-Barr\u00e9 syndrome","author":"Rapha\u00ebl","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.autrev.2021.103019_bb0560","doi-asserted-by":"crossref","DOI":"10.1136\/thx.50.10.1080","article-title":"Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis","volume":"50","author":"Goti","year":"1995","journal-title":"Thorax"},{"key":"10.1016\/j.autrev.2021.103019_bb0565","doi-asserted-by":"crossref","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neuro"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221003013?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997221003013?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:26:16Z","timestamp":1761600376000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997221003013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":112,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S1568997221003013"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2021.103019","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of intravenous immunoglobulin in autoimmune neurological diseases. Literature systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2021.103019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103019"}}